Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

931 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.
Aleman A, Upadhyaya B, Tuballes K, Kappes K, Gleason CR, Beach K, Agte S, Srivastava K; PVI/Seronet Study Group; Van Oekelen O, Barcessat V, Bhardwaj N, Kim-Schulze S, Gnjatic S, Brown B, Cordon-Cardo C, Krammer F, Merad M, Jagannath S, Wajnberg A, Simon V, Parekh S. Aleman A, et al. Among authors: bhardwaj n. Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19. Cancer Cell. 2021. PMID: 34706273 Free PMC article. No abstract available.
Toll-like receptor agonists: are they good adjuvants?
Gnjatic S, Sawhney NB, Bhardwaj N. Gnjatic S, et al. Among authors: bhardwaj n. Cancer J. 2010 Jul-Aug;16(4):382-91. doi: 10.1097/PPO.0b013e3181eaca65. Cancer J. 2010. PMID: 20693851 Free PMC article. Review.
Antigen depots: T cell traps?
Gnjatic S, Bhardwaj N. Gnjatic S, et al. Among authors: bhardwaj n. Nat Med. 2013 Apr;19(4):397-8. doi: 10.1038/nm.3113. Nat Med. 2013. PMID: 23558621 No abstract available.
Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses.
Godefroy E, Gallois A, Idoyaga J, Merad M, Tung N, Monu N, Saenger Y, Fu Y, Ravindran R, Pulendran B, Jotereau F, Trombetta S, Bhardwaj N. Godefroy E, et al. Among authors: bhardwaj n. Cell Rep. 2014 Dec 11;9(5):1856-1870. doi: 10.1016/j.celrep.2014.10.067. Epub 2014 Nov 26. Cell Rep. 2014. PMID: 25466255 Free PMC article.
Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.
Moskalenko M, Pan M, Fu Y, de Moll EH, Hashimoto D, Mortha A, Leboeuf M, Jayaraman P, Bernardo S, Sikora AG, Wolchok J, Bhardwaj N, Merad M, Saenger Y. Moskalenko M, et al. Among authors: bhardwaj n. Cancer Immunol Res. 2015 Mar;3(3):296-304. doi: 10.1158/2326-6066.CIR-14-0120. Epub 2015 Jan 19. Cancer Immunol Res. 2015. PMID: 25600438 Free PMC article.
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg J, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N. Sabado RL, et al. Among authors: bhardwaj n. Cancer Immunol Res. 2015 Mar;3(3):278-287. doi: 10.1158/2326-6066.CIR-14-0202. Epub 2015 Jan 29. Cancer Immunol Res. 2015. PMID: 25633712 Free PMC article. Clinical Trial.
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J, Tung N, Chakarov S, Rivera C, Hogstad B, Bosenberg M, Hashimoto D, Gnjatic S, Bhardwaj N, Palucka AK, Brown BD, Brody J, Ginhoux F, Merad M. Salmon H, et al. Among authors: bhardwaj n. Immunity. 2016 Apr 19;44(4):924-38. doi: 10.1016/j.immuni.2016.03.012. Immunity. 2016. PMID: 27096321 Free PMC article.
931 results